ArticleInflammopharmacology2026
Anti-arthritic appraisal of Acorus calamus L. extracts in complete Freund's adjuvant‑induced arthritic Wistar rats via regulating inflammatory cytokines and OPG/RANKL pathway.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acorus calamus L. is a traditional remedy for inflammatory, neurological, and gastrointestinal disorders. Herein, we explored the anti-inflammatory, antioxidative, and anti-arthritic activities of A. calamus rhizome's extracts using an adjuvant-induced rheumatoid arthritis (AIA) rat model. The maceration method was used to prepare methanol (MEAC) and n-hexane (HEAC) extracts of A. calamus rhizomes, and high-performance liquid chromatography (HPLC) analysis was performed for the quantification of polyphenols. In vivo, 100 µL of Complete Freund's adjuvant (CFA) was injected into the right hind paw to develop AIA in rats. Fifty-four female Wistar rats were divided into nine groups (n = 6) and orally treated with meloxicam (MEL; 3 mg/kg) and three doses (125, 250, and 500 mg/kg/day) of MEAC and HEAC for 28 days. Then, physical, hematological, biochemical, radiological, histopathological, and gene expression analyses were performed. Results indicated that each extract exhibited dose-dependent mitigation of arthritis in AIA rats compared to the standard drug. MEAC and HEAC decreased paw swelling and arthritic scores in a dose-dependent manner, restored body and immune organ weights, normalized hematological indicators (RBCs, Hb, WBCs, and platelets), and significantly reduced serum inflammatory (RF, CRP, TNF-α, and PGE2) and oxidative stress (SOD, CAT, and MDA) markers. Additionally, radiological and histological examinations of MEAC and HEAC administered AIA rats revealed fewer degenerative changes. In particular, both plant extracts (500 mg/kg) persuasively downregulated the expression levels of TNF-α, IL-1β, IL-6, and IL-17 A, upregulated IL-4 and IL-10, and modulated OPG, RANKL, and OPG/RANKL ratio in paw tissues. Moreover, MEAC demonstrated promising pharmacological activity in AIA rats compared to HEAC. Our findings suggest that A. calamus exerts anti-arthritic activity by inhibiting inflammation, potentiating antioxidant defense mechanisms, and subsequently modulating the OPG/RANKL pathway. Thus, A. calamus rhizomes may be a potential natural alternative for the treatment of inflammatory and autoimmune diseases.
Indexed as
Identifiers
41343015What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.